Shopping Cart
Remove All
Your shopping cart is currently empty
Camidanlumab tesirine (Synonyms: ADCT 301)
Catalog No. T9901A-964 Copy Product Info
🥰Excellent
Camidanlumab tesirine (ADCT 301) is an ADC consisting of a human IgG1 antibody, HuMax-TAC, targeting CD25, which is conjugated through a dipeptide-cleavable linker to pyrrolobenzodiazepine (PBD) dimer payloads. The drug-antibody ratio (DAR) of Camidanlumab tesirine is 2.3. It binds to human CD25 with picomolar affinity and exhibits potent and selective cytotoxicity against human lymphoma cell lines expressing CD25.
Camidanlumab tesirine
Copy Product Info🥰Excellent
Catalog No. T9901A-964
Synonyms ADCT 301
Camidanlumab tesirine (ADCT 301) is an ADC consisting of a human IgG1 antibody, HuMax-TAC, targeting CD25, which is conjugated through a dipeptide-cleavable linker to pyrrolobenzodiazepine (PBD) dimer payloads. The drug-antibody ratio (DAR) of Camidanlumab tesirine is 2.3. It binds to human CD25 with picomolar affinity and exhibits potent and selective cytotoxicity against human lymphoma cell lines expressing CD25.
Camidanlumab tesirine
Cas No. 1853239-04-9
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Camidanlumab tesirine (ADCT 301) is an ADC consisting of a human IgG1 antibody, HuMax-TAC, targeting CD25, which is conjugated through a dipeptide-cleavable linker to pyrrolobenzodiazepine (PBD) dimer payloads. The drug-antibody ratio (DAR) of Camidanlumab tesirine is 2.3. It binds to human CD25 with picomolar affinity and exhibits potent and selective cytotoxicity against human lymphoma cell lines expressing CD25. |
| In vitro | Camidanlumab tesirine (ADCT 301; 3, 10 ng/mL; 48 h) causes dose-dependent G2-M phase arrest, peaking at 48 hours. It (10 ng/mL; 24-96 h) induces apoptosis. The compound exhibits a GI50 range of 0.04-2.94 ng/mL in CD25 positive cell lines, but >1,000 ng/mL in CD25 negative cell lines. In both antigen-expressing and non-expressing cell lines, for the unconjugated ADC, the GI50 value is >1,000 ng/mL. |
| In vivo | Camidanlumab tesirine (ADCT 301; 0.1-0.6 mg/kg/day;Intravenous injection; 60 days) inhibits tumor growth in a dose-dependent manner. Its half-life, calculated through analysis of the bound antibody with a DAR component ≥1, is 7.3 days. |
| Synonyms | ADCT 301 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Target | CD25 |
| Cas No. | 1853239-04-9 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Camidanlumab tesirine | purchase Camidanlumab tesirine | Camidanlumab tesirine cost | order Camidanlumab tesirine | Camidanlumab tesirine in vivo | Camidanlumab tesirine in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.